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Abstract
Ghrelin and its synthetic analog hexarelin are specific ligands of growth hormone
secretagogue (GHS) receptor. GHS have strong growth hormone-releasing effect and other
neuroendocrine activities such as stimulatory effects on prolactin and adrenocorticotropic
hormone secretion. Recently, several studies have reported other beneficial functions of GHS
that are independent of GH. Ghrelin and hexarelin, for examples, have been shown to exert
GH-independent cardiovascular activity. Hexarelin has been reported to regulate peroxisome
proliferator-activated receptor gamma (PPAR-γ) in macrophages and adipocytes. PPAR-γ is
an important regulator of adipogenesis, lipid metabolism, and insulin sensitization. Ghrelin
also shows protective effects on beta cells against lipotoxicity through activation of
phosphatidylinositol-3 kinase/protein kinase B, c-Jun N-terminal kinase (JNK) inhibition, and
nuclear exclusion of forkhead box protein O1. Acylated ghrelin (AG) and unacylated ghrelin
(UAG) administration reduces glucose levels and increases insulin-producing beta cell
number, and insulin secretion in pancreatectomized rats and in newborn rats treated with
streptozotocin, suggesting a possible role of GHS in pancreatic regeneration. Therefore, the
discovery of GHS has opened many new perspectives in endocrine, metabolic, and
cardiovascular research areas, suggesting the possible therapeutic application in diabetes and
diabetic complications especially diabetic cardiomyopathy. Here, we review the
physiological roles of ghrelin and hexarelin in the protection and regeneration of beta cells
and their roles in the regulation of insulin release, glucose, and fat metabolism and present
their potential therapeutic effects in the treatment of diabetes and diabetic-associated heart
diseases.
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Introduction
Diabetes mellitus is one of the leading causes of morbidity and mortality worldwide.
Currently, about 382 million people suffer from this disease and by 2035, this will rise to 592
million [1]. Diabetes is classified as type 1 diabetes (T1D), characterized by absolute loss of
insulin production, and type 2 diabetes (T2D), which is a result of both chronic insulin
resistance and loss of pancreatic cell mass and function [2]. T2D is the most common form,
accounting for about 95 % of diabetes [3]. The pathogenesis of T2D involves both genetic
and environmental factors. Obesity is the most common cause of developing T2D as it
represents about 75 % of the causes [4]. Obesity can lead to insulin resistance and impairment
in energy metabolism of most tissues such as skeletal muscles, liver, adipose tissue, and
pancreatic islets. However, insulin resistance does not lead to T2D unless it is accompanied
by pancreatic beta cell dysfunction [5–7].

What are still unknown are the time points when beta cell dysfunction starts and the relative
contribution of beta cell dysfunction in the development of T2D. Current evidence suggested
that islet function was about 50 % of normal at the time of diagnosis [8]. The reduction of
beta cell function most probably starts early about 10–12 years before diagnosis of diabetes
[9]. The major factors for causing progressive decrease in beta cell structure and function
during the course of the disease are glucotoxicity, lipotoxicity, proinflammatory cytokines,
and islet cell amyloidosis [10]. The combined increased flux of free fatty acids and glucose
into the beta cell has detrimental consequences on beta cells [11]. The excess free fatty acid
entering beta cells inhibits proper glucose utilization in the mitochondria. Additionally, it is
reported that these lipids are metabolized in a different way forming lipid intermediates that
cause abnormal signaling and beta cell dysfunction. The glucotoxicity and lipotoxicity also
may cause an increase in reactive oxygen species (ROS) which can damage the cell and then
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lead to beta cell death [12]. The role of the proinflammatory cytokines in causing beta cell
apoptosis had been demonstrated [13, 14]. Macrophages may infiltrate beta cells when they
start becoming damaged. This causes cytokine release from the macrophages, which may
alter the ability of the beta cell to proliferate. Impaired beta cell function and mass could be
reversible at early stages of the disease [15].

Insulin and its downstream signaling pathway play important roles in the homeostasis of
blood levels of glucose, and the disruption of the signaling pathway plays an important role in
the pathophysiology of T2D. Insulin reduces blood glucose levels through increasing glucose
uptake in muscle and fat and decreasing hepatic glucose production. Skeletal muscle
consumes most glucose, accounting for about 75 % of insulin-dependent glucose uptake
while adipose tissue accounts for only a small fraction [16]. The adipose tissue, however, is
crucial in the normal regulation of the insulin action all over the body. Adipocytes can store
excess lipids in obesity but when they become saturated, lipids begin to accumulate inside
other organs, and tissues making them insulin resistant. Adipocytes also can produce
adipokines such as leptin and adiponectin which have been proved as insulin sensitizers due
to their ability to decrease triglycerides (TG) synthesis, to stimulate beta oxidation of fatty
acids, and thus to enhance insulin action in both skeletal muscle and liver [17–19].

Genetically modified animals deficient in white adipose tissue usually have severe insulin
resistance in liver and muscle [20]. Transplantation of normal fat tissue into white adipose
tissue deficient mice restores the insulin sensitivity [21]. Mice with a knockout of the insulin
receptor in muscle have normal glucose tolerance [22], whereas those with a knockout of the
insulin-sensitive GLUT4 glucose transporter in adipose tissue have impaired glucose
tolerance, apparently due to insulin resistance being induced in muscle and liver [23]. Other
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recent Studies reported that obesity promotes inflammatory signals especially in the adipose
tissues that disrupt insulin action and mediate insulin resistance [24]. Accordingly, the
therapeutic targets of T2D will be preservation of beta cell structure and function, enhancing
metabolic activity especially of the adipose tissues and decreasing lipid content in different
tissues. In this review, we will focus on the possible roles of ghrelin, a natural ligand of the
growth hormone secretagogue receptor type 1a (GHS-R1a), and hexarelin, a synthetic
peptidyl GHS in the treatment of diabetes and diabetic-associated heart diseases.

Growth Hormone Secretagogues (GHS)
GHS are substances which stimulate the release of GH from the pituitary. They include the
natural endogenous one, ghrelin, which is predominantly produced by A-like cells of the
stomach from its precursor proghrelin [25] and synthetic peptidyl and non-peptidyl
molecules. The ghrelin peptide is acylated to acylated ghrelin (AG) by the enzyme ghrelin-Oacyltransferase (GOAT) [26]. AG is present in serum at a 2.5-fold lower concentration than
unacylated ghrelin (UAG) [27]. UAG has been thought for a long time to be an inactive
metabolite of AG [25, 27]. However, it is now recognized that UAG may exert
physiologically relevant effects through an unidentified receptor. UAG can antagonize the
effect of AG [28, 29]. However, in some cases UAG acts synergistically with AG [30] or
have AG-independent effects [31]. UAG seems to oppose the effect of AG at the metabolic
levels such as insulin secretion and food intake but cannot counteract it at the neuroendocrine
levels like GH release, prolactin or adrenocorticotrophic response [27]. Most of the effects of
AG appear to be mediated through activation of GHS-R1a, as the specific receptor
antagonist, [d-Lys3]-GHRP-6 completely blocks the protective effects of ghrelin against
oxygen–glucose deprivation insult [32]. In contrast, Baldanzi et al. reported that in
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cardiomyocytes ghrelin exhibits an antiapoptotic effect through binding to a novel,
unidentified receptor that is distinct from GHS-R1a [33].

The GHS-R is a G protein-coupled seven-transmembrane domain receptor and was initially
identified as a receptor for small synthetic molecules GHS, such as hexarelin, L-692,429,
GHRP-6, and MK-0677, all of which stimulate GH secretion from the pituitary [34, 35]. The
GHS-R has two forms GHS-R1a and GHS-R1b. The GHS-R1a is the functionally active and
signal transducing form of the GHS-R, whereas the GHS-R1b is devoid of high-affinity
ligand-binding and signal transduction activities [36]. Expression of the GHS-R1a receptor
was shown in the hypothalamus and anterior pituitary gland which is consistent with its role
in regulating GH release [35, 37]. GHS-R1a receptor is also expressed in many peripheral
organs. GHS-R1a receptor mRNA was shown in the stomach and intestine [38], pancreas
[34], kidney [39], heart, and aorta [40], as well as in different human pituitary adenoma and
various endocrine neoplasms of different organs [41–43]. These findings indicate that ghrelin
and synthetic GHS have many functions other than the control of GH release. Ghrelin and
synthetic GHS are potent stimulators of GH release [44–46]. However, the activity of both
ghrelin and synthetic GHS is not fully specific for GH and includes stimulatory effect on both
lactotroph and corticotroph secretion [46, 47]. Ghrelin enhances Appetite and increases food
intake in humans [48] and animals [49] either injected centrally [50, 51] or peripherally [48,
52]. Ghrelin has been shown to have many protective effects on the cardiovascular system
[53–56]. Ghrelin also has been proved to be a potent anti-inflammatory mediator both in vitro
and in vivo in lymphocytes, monocytes, and dendritic cells and promoting IL-10 expression
and cell migration [57].
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The synthetic, peptide GHS are also known as growth hormone-releasing peptides (GHRPs).
GHRP-6 was the first hexapeptide shown to release GH in vivo, especially in humans after
oral administration with low bioavailability and short-lasting effect [58, 59]. Recently,
heptapeptide, GHRP-1, and two other hexapeptides, hexarelin and GHRP-2, have been now
synthesized [60, 61]. Hexarelin (His-d-2MeTrp-Ala-Trp-d-Phe-Lys-NH2) differs from
growth hormone-releasing peptides GHRP-6 by having a methyl group in position 2 of the
DTrp [62]. This minor modification was beneficial, making hexarelin more stable and longer
acting in vivo [63]. Hexarelin is more potent than GHRP-6 as a GH releaser [64–66].
Hexarelin has many physiological actions independent of growth hormone such as the
protection against cardiac ischemia and impairment of vascular endothelium function in the
hearts of GH-deficient rats [67, 68]. GHS-R1a seems to mediate the action of hexarelin.
However, some studies have reported that the CD36 receptor mediates the action of hexarelin
in the heart and mouse 3T3-L1 preadipocytes [69, 70]. Our review will concern on the
functions of ghrelin and hexarelin in the protection, regeneration of beta cells, regulation of
insulin release, glucose metabolism, and their possible uses in treatment of diabetes and heart
diseases.

Effects of ghrelin on pancreatic beta cells.
Ghrelin has been shown to promote survival and inhibit apoptosis in many cell types. Ghrelin
protected human endothelial cells against apoptosis caused by high glucose [71]. Treatment
of 3T3-L1 preadipocytes with ghrelin inhibited adipocyte apoptosis induced by serum
deprivation, induced cellular proliferation and differentiation to mature adipocytes. Ghrelin
also increased the basal and insulin-stimulated glucose transport in theses adipocytes [72].
Ghrelin has been confirmed to have protective effects against different stressful factors
including TNF-alpha [73] and doxorubicin [33]. Hexarelin is able to both increase cell
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proliferation and protect adult rat hippocampal progenitor (AHP) cells from apoptosis and
necrosis induced by growth factor deprivation [74]. Interestingly, ghrelin is recently shown to
protect beta cells from apoptotic effect of saturated fatty acids [75]. It is obvious in many
studies that prolonged exposure of isolated islets or beta cell lines to saturated fatty acids is
associated with beta cell apoptosis [76–78]. The signaling pathways that regulate pancreatic
beta cell apoptosis during lipotoxicity or the oxidative stress could be inactivation of
phosphatidylinositol-3 kinase/protein kinase B (PI3K/AKT), sustained c-Jun N-terminal
kinase (JNK) activation, phosphorylation of forkhead box protein O1 (Foxo1) at serine and
threonine sites distinct from those phosphorylated by AKT, enhancing the nuclear retention
of Foxo1 [79, 80]. However, it is unclear whether inhibition of AKT or activation of JNK
precedes inhibition of Foxo1 nuclear translocation or if there is a crosstalk between
PI3K/AKT activation and JNK inhibition. Therefore, further studies are needed to clarify the
mechanisms of these signaling molecules in the protection of beta cells from apoptosis.
Ghrelin has been shown to exert the antiapoptotic effects on beta cells via G protein-coupled
receptor/CAMP/PKA, activation of PI3K/AKT, and extracellular signal-regulated kinase
(ERK) [81, 82] (See Fig. 1). Wang et al. has demonstrated that ghrelin inhibits the apoptosis
and promotes beta cell proliferation through nuclear exclusion of Foxo1 and inhibition of
endoplasmic reticulum (ER) stress pathway [83].

AG increased insulin expression and secretion and PDX1 mRNA in the pancreas of STZtreated rat [84]. PDX1 is a transcriptional factor which is essential for insulin transcription
and maintenance of beta cell mass [85]. Similarly, UAG and obstatin, which is encoded in the
same gene as ghrelin, increased islet area, islet number, and beta cell mass and insulin and
PDX1 mRNA compared to the pancreas of STZ-treated rat and also increased the expression
of antiapoptotic gene, BCL-2 [86]. Both UAG and AG induced cell survival and protection
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against apoptosis in isolated human islets of Langerhans [82, 87]. The insulin-positive beta
cells in these islets expressed GHS-R1a, explaining the mechanism of action for AG.
However, the radiolabelled binding studies for UAG suggest that these islets also express
UAG and AG binding sites that are probably not the classical GHS-R1a [82]. Therefore, the
effects of UAG and AG may also occur via mechanisms independent of the GHS-R1a, likely
mediated by specific AG and UAG binding sites. Taken together, these findings indicate that
the binding sites of AG and UAG are different or may be some GHS-R subtypes could
recognize and bind ghrelin independently of its acylation. However, the downstream
signaling mechanisms in protecting beta cells may be the same for both peptides via the
activation of PI3K/AKT and extracellular signal-regulated kinase (ERK) (as shown in Fig. 1).
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islet cell proliferation and survival (GHS-R1a GH secretagogue receptor type 1a,
PI3K phosphatidylinositol 3-kinase, MAPK Mitogen-activated protein kinases
(MAPK), ERK1/2 extracellular signal-regulated kinase 1/2, NO nitric oxide, PDX1
pancreatic and duodenal homeobox-1, JNK Jun-N-terminal kinase, Foxo1
Forkhead transcription factors of the FoxO family).

Moreover, some studies have reported the potential roles of ghrelin in the regeneration of
beta cells. Beta cell regeneration is an alternative strategy to replace islets transplantation
especially with the shortage of pancreatic donors [88]. Pancreatic regeneration requires
expansion of beta cells through beta cell neogenesis, dedifferentiation of acinar cell to beta
cells, and proliferation of progenitor beta cells [89, 90]. Various agents have been studied to
increase pancreatic regenerative capacity; the most important ones are glucagon-like peptide
1, actin, members of the transforming growth factor beta family, and the polypeptide growth
factor beta [91–93]. Interestingly, ghrelin has been reported to influence the embryologic
development of the pancreas and to regulate insulin secretion [94, 95]. Rats received 90 %
pancreatectomy (surgical removal of 90 % of pancreas) were shown to have severe
hyperglycemia and decreased beta cell mass and insulin levels. AG administration strongly
reduced glucose levels, increased insulin-producing beta cell number, and insulin secretion.
On the contrary, ghrelin receptor antagonist [d-Lys3]-GHRP-6 administration in these
pancreatectomized rats worsens glucose levels and decreases beta cell mass [96]. AG, UAG,
and obstatin counteracted the hyperglycaemia and improved plasma and pancreatic insulin
levels, which were reduced by the STZ compound in newborn rats treated with STZ [84].
UAG and Obstatin increased islet area, islet number, and beta cell mass with respect to STZ
treatment alone [86]. These findings strongly suggest that beta cells damaged by STZ
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administration during the neonatal stage or reduced by pancreatectomy can be regenerated or
replicated following ghrelin treatment. This ability of GHS to regenerate beta cells may be
supported by previous studies that have shown the regeneration effect of GH itself on the
pancreas [97]. In conclusion, these findings provide evidence that GHS may function as a
survival and regenerative factor for beta cells and offer a new perspective on the potential
role of these peptides in diabetes.

Effects of ghrelin and hexarelin on insulin secretion and glucose homeostasis
The role of the ghrelin in the regulation of insulin secretion and insulin action remains a
controversial topic. Ghrelin is reported to either inhibit or stimulate insulin secretion in
animals (as shown in Table 1) and humans (as shown in Table 2). The discrepancies of
ghrelin effects in different studies may be due to the following reasons: (1) the implications
of ghrelin on insulin secretion and glucose metabolism could be different in different energy
states like fasting, fed, obese, and diabetic, (2) Ghrelin, GHS-R, and GOAT are all expressed
in pancreatic islets, suggesting a role for locally expressed ghrelin that could be different
from that of the systemic ghrelin in the regulation of insulin release, (3) some of effects of
ghrelin are independent of GHS-R1a and this highlight the complexity of the ghrelinsignaling pathway. This can be indicated by the paradoxical effects of ghrelin ablation and
GHS-R ablation in ob/ob mice [98], (4) the controversy could be also due to differences in
experimental design (different doses, different times of observation, mode of injection, in
vitro versus in vivo experiments, etc.). This is obvious in one study that tested the effect of
different concentration of ghrelin on insulin release. The study showed that ghrelin
concentrations in the physiological range had no effect on glucose-stimulated insulin
secretion (GSIS), while low ghrelin concentrations inhibited and high stimulated it [99]. The
insulin response to glucose was enhanced in the presence of a high ghrelin concentration.
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Another study showed that the subcutaneous administration of ghrelin induced relatively
specific GH release and enhanced cardiac performance in humans without significant adverse
effects [99], and (5) long-term versus short-term actions of the peptide. In one study, the
stimulatory action of ghrelin on insulin levels in rats was observed at 15 min but not at 5 min
after ghrelin administration [100]. Therefore, the net effect on insulin sensitivity of
manipulation of the ghrelin system still remains to be determined, although the overall
systemic effects suggest promoting insulin resistance.

AG levels may be an important predictor of the glucose control under physiological
conditions [101]. Ghrelin clearly stimulated insulin-mediated glucose disposal, an
observation that was consistent with enhanced 2-deoxy-d-[3H]glucose (2DG) uptake in
muscle and adipose tissue during hyperinsulinemia in ghrelin-treated animals [102]. In
contrast, ghrelin hampered inhibition of endogenous glucose production by insulin.
Furthermore, simultaneous administration of UAG abolishes the inhibitory effect of ghrelin
on hepatic insulin action [102]. AG and UAG have been proposed to have opposite effects on
glucose metabolism, which suggests a potentially significant influence of them on glucose
metabolism [103]. Transgenic mice overexpressing ghrelin under the rat insulin II promoter
had a pancreatic UAG content that was 1,000 times higher than the control mice. Such mice
showed reduced GSIS and lower blood glucose levels and triglyceride levels during insulin
tolerance test [104]. The suppression of insulin secretion is likely due to the enhancing effect
of UAG on insulin sensitivity. Insulin secretion from isolated islets was instead
indistinguishable from that of non-transgenic mice. These results imply that UAG, opposite
to AG, increases insulin sensitivity. Gauna et al. reported that administration of AG in
humans reduces insulin sensitivity, whereas the combination of AG plus UAG strongly
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improves insulin sensitivity [105]. Another studies reported that the dysregulation of
AG/UAG ratio could play a role in pathogenesis of insulin resistance and diabetes [106, 107].

Ghrelin influences insulin and glucose homeostasis through a range of central and peripheral
GHS-R-mediated mechanisms. Glucose and insulin also influence ghrelin secretion [108,
109]. Ghrelin influences glucose homeostasis centrally through medial hypothalamus. Reexpression of GHS-R in hypothalamic neurons expressing agouti-related peptide (AgRP) of
adult GHS-R-null mice restores the orexigenic response to administered ghrelin and lowered
blood glucose levels during caloric restriction [110]. This normalized glucoregulatory
response was associated with glucagon rises and hepatic gluconeogenesis, indicating that
hypothalamic arcuate-expressing agouti-related peptide (AGRP) neurons are responsible for
the orexigenic effects and the central effects of ghrelin on glucose homeostasis. The effect of
hexarelin on blood insulin, glucose, and in general on type 2 diabetes mellitus has not been
studied well yet. In one study, obese and lean male rats of the Zucker strain were treated with
hexarelin (80 μg/kg, b.i.d., s.c.) or saline (1 ml/kg, b.i.d., s.c.) for 30 days [111]. The results
showed an increase in plasma insulin concentration in the obese rats treated with hexarelin.
Obese rats treated with saline had plasma glucose concentrations similar to those found in
lean animals. Treatment with hexarelin increased plasma glucose concentrations in obese rats
but not in lean rats. One possibility of these findings may be related to the ability of hexarelin
to stimulate the hypothalamic–pituitary–adrenal (HPA) axis [112, 113]. However, the
mechanism by which GHS stimulate the HPA axis is unknown.
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Table 1. The in vivo and in vitro effects of ghrelin on insulin secretion and glucose
homeostasis in animals.
Model

Treatment

Dose and mode of

Insulin

adminstration

Refer
ences

Rat pancreatic islets

AG

10-12 M in vitro

Increased GSIS.

Isolated pancreas from

AG

10-9 M in vitro

Increased insulin release from [115]

normal and STZ treated rats

[114]

the pancreas of normal and
diabetic rats.

Wistar rats with 90%

AG

pancreatectomy

STZ-treated neonatal rats.

AG

*I.P. (10 nM /Kg/day)

Increased plasma insulin from [96]

in the first postoperative

the 15th postoperative day

day.

and reduce plasma glucose.

*S.C. (100 μg/kg/ day) for

No changes in blood glucose

7 days (from day 2 to 8)

or insulin levels between the

after birth.

STZ and STZ/Ghrelin groups.

[84]

Significant increase in insulin
expression and insulin mRNA
in pancreas of STZ/Ghrelin
groups.
HIT-T15 insulin-producing

AG or

cells

UAG.

100 nM in vitro

Increased GSIS. UAG being

[82]

more potent than AG at
raising insulin levels.

STZ-treated neonatal rats

AG or UAG

S.C. (100 μg / kg, twice

AG or UAG reduced glucose

daily), from day 2 to 8

levels, restored plasma

after birth.

insulin and pancreatic insulin.

15

[86]

GH-deficient little mice and

AG or UAG I.P. (1 and 10 nM / kg).

control wild mice

AG decreased insulin and

[116]

elevated blood glucose levels.
UAG failed to significantly
alter blood glucose levels.
AG at 10 nmol/l, but not 0.1
nmol/l and 1 pmol/l,
decreased GSIS in islets.

Perfused pancreas from

AG or UAG 10 nM in vitro

AG suppressed both phases

male wister rats &

of GSIS.

isolated islets from male

UAG has no effect.

ghrelin knockout and

Ghrelin knockout mice

wild-type mice

display increased insulin and

[117]

decreased glucose levels.
Increase GSIS from isolated
islets of ghrelin knockout
mice.
Min6 cells with

AG

10 nM in vitro

Inhibited GSIS.

[118]

AG

10 nM in vitro

No change of basal insulin

[119]

overexpression of UCP-2
Isolated rat pancreas

release but markedly
inhibited GSIS and insulin
release elicited by 1 mM
carbachol.
Isolated rat islets & INS-

AG

10 nM for isolated islets &

1E cells

Inhibited GSIS in both the
isolated islets and cell line.

16

[120]

1 nM for INS-1E cells

INS-1E cells

AG (rat,

10 nM in vitro

AG or UAG increased GSIS.

[121]

*I.V. (25 nmol) into the

Increased insulin significantly [100]

jugular vein.

at 15 and 60 min after the

human or *
Dap
octanoylate
d human)
or UAG (rat
or human)
Male Sprague

AG

Dawley rats

injection, compared with
control.
Female C57BL/6J mice & AG

I.V. (50, or 150 nM/kg)

Inhibited plasma insulin. No

isolated islets from mice

with glucose at the dose of

effect on insulin sensitivity.

1 g/kg in a tail vein and

Inhibited GSIS from isolated

0.01 - 1 nM for the

islets.

[122]

isolated islets
*Adult male WT, ghrelin−/−,

Lowered insulin

and Ghsr−/− mice

concentrations in both
ghrelin−/− and Ghsr−/− mice
compared with WT mice
during the postabsorptive
state.
No change in blood glucose

17

[123]

between the three groups.
*I.P.: intraperitoneal injection.
*S.C.: subcutaneous injection.
*I.V.: intravenous injection.
*Dap-octanoylated human ghrelin (DapAG), a ghrelin molecule where the octanoyl group on the third serine residue is stabilized by a αand β-diaminopropanoic acid.
*WT (wild type), ghrelin−/−(ghrelin knockout) and Ghsr−/−( growth hormone secretagogue receptor knockout) mice.
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Table 2. The effects of ghrelin on insulin secretion and glucose homeostasis in humans.
Morbidly obese non-

UAG or UAG

I.V.: UAG: 200 ug

UAG +AG decreased insulin

diabetic subjects

+AG

or UAG 100 ug +

and no effect on blood glucose.

AG 100 ug for 4

UAG had no effect on blood

days

glucose or plasma insulin.

AG (0.3, 0.9 and

AG decreases GSIS and worsens

1.5 nmol/kg/h) or

intravenous glucose tolerance in

saline was infused

healthy humans.

Healthy subjects

AG

[124]

[125]

for more than 65
min
Obese and normal

AG

I.V. 1μg/kg

Increased glucose and reduced

women

[126]

insulin in obese women and
increased glucose but not insulin
in normal women.

Normal young

AG

I.V. 1μg /kg

Inhibited insulin and increased

subjects

[127]

glucose levels. Ghrelin did not
modify both glucose and insulin
responses to *OGTT

Normal young

AG or UAG

I.V. 1 μg /kg

subjects

AG decreased in insulin levels

[128]

and increased in blood glucose
UAG has no effect

Healthy or

AG or AG +

AG: 1 μg/kg

AG and to a lesser extent UAG

hypopituitary

UAG

UAG: 1 μg/kg

induced significant

humans

hyperglycemia. No increase in
blood glucose when GH was
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[105]

administered 15 min before the
administration of AG. AG +
UAG seemed to lower serum
glucose levels significantly.
AG + UAG induced a significant
reduction in serum insulin.
Healthy,

*EHC: AG

AG: I.V. 5 pmol/kg Decreased insulin sensitivity

gastrectomized

per minute 5 h

or hypopituitary

pancreatic clamp

[129-131]

humans
Healthy humans

EHC: AG 5 h

6.25 mg/l

Increased insulin sensitivity

(intramuscular)
*OGTT: Oral glucose tolerance test
*EHC: Euglycemic / hyperinsulinemic clamp
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[132]

Effects of ghrelin and hexarelin on adipose tissue.
The effect of ghrelin on adipose tissue has also been reported. Ghrelin increased the insulinstimulated deoxyglucose uptake in isolated white adipose tissue from epididymal fat at
concentration of 1,000 nM compared to 0.1 nM insulin alone. Ghrelin increased slightly the
glucose uptake at 100 nM without statistical significance [133]. AG did not increase the
deoxyglucose uptake in peri-renal adipocytes, which does not express GSH-R1a. UAG had
no effect on insulin-stimulated glucose uptake. The dose of ghrelin in this study was above
the physiological plasma concentration of ghrelin which could be explained by the difference
in the effect and the dose of local and systemic ghrelin. The local ghrelin concentrations in
adipose tissues may be considerably higher than those in the circulation and systemic ghrelin
could be less important in the modulation of glucose uptake than those found locally. Ghrelin
enhanced insulin-stimulated glucose uptake in adipocyte cell line, 3T3-L1 [72]. On the
contrary, Ott et al. reported that ghrelin pre-treatment had no effect on insulin-stimulated
glucose uptake in an immortalized brown adipocyte cell line [134]. Consequently, ghrelin
appears to directly potentiate adipocyte insulin-stimulated glucose uptake in selective
adipocyte populations and may play a role in adipocyte regulation of glucose homeostasis.
Also, ghrelin regulate cholesterol efflux in macrophages through a GHS-R1a/PPAR-γdependent pathway [135]. Interestingly, these studies showed that PI3K/AKT pathway is
mediating PPAR-γ activation by ghrelin which is the same pathway that mediates the
antiapoptotic effects of ghrelin on various cells.

The potential effects of hexarelin on lipid metabolism have been studied. Hexarelin through
binding to CD36 receptor induced an increase in thermogenic coactivator PGC-1α and
uncoupling protein-1 (UCP-1) in 3T3-L1 adipocytes as well as in epididymal fat of treated
mice, indicating increased fatty acids metabolism in the white fat in response to hexarelin
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[70]. Hexarelin treatment in obese rats significantly decreased plasma cholesterol but not
triglyceride levels [111]. In another study, apolipoprotein E-null mice maintained on a longterm, high-fat, and high-cholesterol diet, a condition known to cause atherosclerosis, showed
a significant regression in atherosclerotic lesions when treated with hexarelin compared to
saline-treated controls [136]. This study demonstrated the activation of the PPAR-γ- liver X
receptor (LXRα)-ATP-binding cassette transporters (ABC) metabolic cascade could be the
signaling pathway for the action of hexarelin to cause the macrophages to mobilize excess
cholesterol into the HDL cholesterol reverse pathway. These beneficial effects of hexarelin
were observed under conditions in which GH was not upregulated, and similar effects
observed in mice treated by EP80317, a hexarelin derivative with no GH release activity,
supporting a GH-independent role for hexarelin [137].

These effects of hexarelin derived from enhanced expression of PPAR target genes, resulting
in a thermogenic-like profile. PPAR-γ is considered a master regulator of fatty acid
metabolism in fat through its direct role in regulating the expression of a broad range of genes
involved in fatty acid and glucose metabolism [138]. Among the genes upregulated by
PPAR-γ, genes related to fatty acid uptake (fatty acid transport protein FATP, CD36),
glucose uptake (GLUT4), β-oxidation (acyl-CoA dehydrogenase, carnitine
palmitoyltransferase CPT-1, acyl-CoA oxidase), gluconeogenesis (phosphoenolpyruvate
carboxykinase PEPCK), and lipid storage (adipophilin). PPAR-γ also plays a central role in
coordinating the macrophage response to lipid loading through a transcriptional cascade
involving LXRα and the ABC transporters A1 and G1 [139, 140]. Similarly, PPAR-γ
agonists of the thiazolidinedione family were shown to exert beneficial anti-diabetic and antiatherosclerotic actions by promoting activation of the PPAR-γ-LXRα-ABC pathway and
cholesterol efflux [141, 142]. Consequently, we suppose that ghrelin or hexarelin by
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modulation of PPAR-γ activity could enhance insulin sensitivity, regulate cholesterol
metabolism in macrophages, and prevent atherosclerotic vascular lesion progression.
Recently, hexarelin also inhibited cholesterol synthesis in liver cells through the activation of
the adenine monophosphate-activated protein kinase (AMPK) pathway, reduction of 3hydroxy-3-methylglutaryl-CoA reductase (HMGR), and increase recruitment of the anchor
proteins insulin-induced genes (Insig-1 and Insig-2) in the liver cells [143]. HMGR is the
rate-limiting enzyme in the cholesterol biosynthesis pathway. These findings support that
CD36 and its ligands such as hexarelin play a role in regulating AMPK activity fatty acid
metabolism and reverse cholesterol transport.

Ghrelin and hexarelin promote mitochondrial activity and biogenesis
The cause of apoptosis and failure of beta cell that occur during T2D are still unknown.
However, mitochondria may play a role in regulating apoptosis and insulin secretion [144,
145]. Many studies have reported the beta cells in T2D do not sense glucose properly and
consequently do not release enough amounts of insulin. The increased glucose and fatty acids
could cause beta cell mitochondrial damage, leading to decreased ATP due to increase of
mitochondrial membrane potential and production of ROS [146] (as shown in Fig. 2). Beta
cells are susceptible to oxidative stress due to the weak expression of antioxidative enzymatic
defenses, e.g., catalase and superoxide dismutase (SOD). Increased ROS can cause leakage of
protons into the mitochondrial matrix, leading to decreased ATP production, and thus
reduced GSIS [147]. Uncoupling protein 2 (UCP-2) modulates coupling efficiency and may
regulate GSIS [148]. A small reduction in the mitochondrial membrane potential induced by
mild uncoupling has a significant effect in attenuating ROS production [149]. However, the
increase mitochondrial UCP2 decreases GSIS by decreasing intracellular ATP/ADP ratio
[148].
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It was interesting to observe that hexarelin and ghrelin enhanced mitochondrial structure and
metabolism by upregulating many genes related to the mitochondrial metabolism of glucose
and fatty acids [70]. More specifically, the upregulation of the genes which encode acetyl
CoA acyl transferase, CPT-1, and several subunits of the ATP synthase and cytochrome c
oxidase complexes may suggest an increased fatty acid metabolism through the
mitochondrial oxidative phosphorylation pathway. The mitochondria of hexarelin-treated
3T3-L1 adipocytes showed an intense and highly organized cristae formation that spanned
the entire width of mitochondria compared to that in untreated cells as shown by the electron
microscopy [70]. Ghrelin also exerts a protective effect against H2O2-induced apoptosis in
H9c2 rat cardiomyocytes by reducing the proapoptotic protein Bax and increasing Bcl-2
expression, accompanied by decreasing activation of caspase-9 and caspase-3 [150]. These
results demonstrate that the antiapoptotic effect of ghrelin is probably caused by decrease
H2O2-induced mitochondrial stress and by blocking activation of NF-κB. The transcription
factor NF-κB is a critical signaling molecule in oxidant stress responses. UCP-2 mRNA
expression was downregulated in INS-1 beta cell by ghrelin in the presence of 26.4 mM
glucose [151]. Other studies showed that ghrelin decreased oxidative injury in the stomach
[152], brain [153], blood vessels [154], and liver [155].
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products (AGEs) and collagen [160, 161]. Functionally, there are diastolic abnormalities
which have been suggested as early functional abnormalities of diabetic CM [162, 163]. The
cardioprotective effects of hexarelin and ghrelin have been well investigated. Many studies
have shown their beneficial effects on the cardiovascular system such as protection against
cardiac ischemia, cardiac fibrosis, improving cardiac function, and decreasing peripheral
resistance after myocardial infarction (MI) in animals [164–166] and humans [167]. Our
group showed that treatment of spontaneously hypertensive rats (SHRs) with hexarelin for 5
weeks from an age of 16 weeks significantly reduced cardiac fibrosis in SHRs by decreasing
interstitial and perivascular myocardial collagen deposition and myocardial hydroxyproline
content and reducing mRNA and protein expression of collagen I and III in SHR hearts [168].
In addition, hexarelin treatment significantly attenuated left ventricular (LV) hypertrophy, LV
diastolic dysfunction, and high blood pressure in SHRs. So, our data demonstrate that
hexarelin reduces cardiac fibrosis in SHRs, perhaps by decreasing collagen synthesis and
accelerating collagen degradation [168].

Ghrelin and hexarelin showed protective effects on cardiac ischaemia. Administration of
ghrelin in vitro to ischaemia/reperfusion (I/R) rat hearts was shown to reduce the infarct size
through the activation of PKC, and these effects were likely initiated by the binding of
ghrelin to its receptor, GHS-R1a [169]. Pre-administration of ghrelin in vivo greatly
ameliorated the damaged heart function, attenuated myocardial injury, and apoptosis through
inhibition of ER stress [170]. The role of hexarelin on the protection against cardiac ischemia
has been reported earlier [67, 68, 171]. Rats pre-treated with ghrelin or hexarelin for 7 days in
vivo prior to in vitro I/R injury showed an improvement in cardiac function [172]. A single
dose of oral hexarelin treatment at the very acute phase after MI has protective effects on
chronic cardiac function [173]. Aragno et al. also showed that obestatin, which is encoded by
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the same gene for ghrelin, protected STZ-caused myocardial dysfunction [174]. Our group
has confirmed the protective effect of hexarelin and ghrelin on cardiac ischaemia [164].
Ghrelin (10 nM) or hexarelin (1 nM) was administered in the perfusion solution of isolated
hearts before or after ischemia for 10 min. It was found that relative sarcomere shortening
was significantly reduced after I/R and exhibited a reduction in both the amplitude and rising
rate of intracellular calcium ([Ca2+]i) transients but increases in cytoplasmic [Ca2+]. The
alternation in [Ca2+]i transients and cytoplasmic [Ca2+] which occurs during the cardiac
ischemia and reperfusion is due to reduction of sarcoplasmic reticulum (SR) Ca2+ ATPase
and Na/K ATPase activities or due to increased oxidative stress which occurs during the
reperfusion which leads to subsequent damage to the plasma and SR membranes and further
increases in cytoplasmic Ca2+. Pre- and post-treatments with ghrelin and hexarelin protected
freshly isolated mouse ventricular cardiomyocytes against these negative effects of I/R. They
resulted in normal cardiomyocytes contractility, normal amplitude, and rising rate of [Ca2+]i
transients in the cardiomyocytes during an in vitro I/R injury, which could be attributed to
normalized SR Ca2+ ATPase activity and SR Ca2+ content [164].

To compare the effect of ghrelin and hexarelin on cardiac function after infarction MI,
ghrelin-knockout mice were used to show whether hexarelin could compensate for the ghrelin
deficiency [175]. The results showed that hexarelin-treated mice had better cardiac function
than ghrelin-treated mice, as indicated by the higher absolute values of percent of the ejection
fraction (EF), peak rate of pressure rise (dP/dt max) and dP/dt min, fractional shortening
(FS), preload-adjusted maximal power (PAMP), and maximal elastance (Emax). Hexarelin
and ghrelin treatments also significantly reduced collagen volume fraction in the noninfarcted LV walls and plasma atrial natriuretic peptide levels than vehicle administration
[175]. These stronger effects of hexarelin was also confirmed by another study in which
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hypophysectomized rats were treated in vivo for 7 days with either ghrelin (320 g/kg) or
hexarelin (80 g/kg), and then their hearts were subjected in vitro to the ischemia and
reperfusion procedure [172]. Ghrelin was far less effective than hexarelin in preventing
increases in LV end-diastolic pressure (15 and 60 % protection for ghrelin and hexarelin,
respectively), coronary perfusion pressure (10 and 45 % reduction), and release of creatine
kinase in the heart perfusate (15 and 55 % reduction). The effects of hexarelin were mediated
largely by interactions with CD36 in the heart and to a lesser extent by GHS-R. However,
other studies reported that ghrelin and hexarelin had similar effects [176].

In addition, AG and UAG also exert antiapoptotic effects on mouse and rat cardiomyocytes
by acting on MAPK and PI3K/AKT pathways [33]. Similarly, our studies have confirmed the
cardioprotective role of hexarelin in I/R models of hearts from mice [164]. GHS can preserve
the electrophysiological properties of cardiomyocytes after I/R and inhibit cardiomyocyte
apoptosis and promote cell survival by modification of MAPK pathways through activating
GHS-R1a [176]. Hexarelin also showed a protective role on angiotensin II (ANG II)-induced
apoptosis of isolated cardiomyocytes from neonatal rats [177]. Administration of hexarelin
significantly decreased ANG II-induced apoptosis and DNA fragmentation and increased
cardiomyocyte viability via inhibiting the increased caspase-3 activity and BAX expression
and by increasing the expression of BCL-2. GHS-R mRNA was abundantly expressed in
cardiomyocytes and was upregulated after administration of hexarelin.

Recently, some studies have reported that the beneficial effect of ghrelin on the
cardiovascular system might be mediated by modulation of cardiac autonomic nerve activity.
Ghrelin has been shown to suppress sympathetic activity and to decrease blood pressure
through mechanisms involving the central nervous system [178, 179]. The beneficial effects
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of ghrelin were accompanied by the suppression of MI-induced increase of heart rate and
plasma norepinephrine concentration [180]. These effects of ghrelin decreased with atropine
pre-treatment or vagotomy. Ghrelin exerted antiarrhythmic effects in rats during acute MI via
modulation of vagal activity by showing increased high-frequency (HF) component as an
index of parasympathetic activity and decreased low-frequency (LF)/HF ratio as an index of
sympathetic activity and restoration of phosphorylated connexin-43 protein levels [181].

As connexin-43-deficient mice have been reported to be markedly susceptible to ischemiainduced ventricular arrhythmias [182]. Other studies have been proposed to explain the
reduction in blood pressure after ghrelin administration, including vasodilation via
endothelium activation or a direct effect on vascular smooth muscle cells [183, 184]. Ghrelin
also inhibited post-infarct myocardial remodeling, while improving cardiac function through
its anti-inflammatory effects as shown by decreased mRNA and protein levels of interleukin1beta and tumor necrosis factor-alpha [185].

Clinical studies in human with growth hormone deficiency (GHD) suggested that patients
with either ischemic or non-ischemic CM might benefit from GHS therapy, mainly from
reduction of LV maladaptive remodeling and cardiomyocyte loss. In healthy volunteers and
in patients with GHD, an acute administration of hexarelin (2 µg/kg) elicited a short-term
increase in contractility and LV ejection fraction in a GH-independent manner [186]. Similar
results were observed in patients with ischemic CM but not with dilated CM [187]. Studies
with ghrelin showed an improved cardiac function following acute administration, although
this effect was associated with a dose-dependent increase in GH [188]. Also, a short-term
infusion of ghrelin (0.1 µg/kg/min60 min) decreased mean arterial pressure and increased
cardiac and stroke volume index, which may be related to a reduced systemic vascular
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resistance in healthy volunteers and in patients with heart failure. The cardiovascular effects
of GHS could be through GHS-R1a in the heart and the blood vessels or through CD36 that is
a specific cardiac receptor for hexarelin [189].

Conclusions
The exact mechanisms by which GHS promote their metabolic response are not fully
understood. However, it becomes clear that interacting with GHS-R1a and/or other receptors
induces profound changes in metabolic activities of target tissues, especially regarding
PPAR-γ-downregulated events. These metabolic effects besides the proliferative,
regenerative, and antiapoptotic effects of GHS on beta cells represent a promising avenue in
the treatment of diabetes and diabetic related heart diseases.
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